Skip to search formSkip to main contentSkip to account menu

Dipeptidyl Peptidase-4 Activity Measurement

Known as: DPPIV Activity, Dipeptidyl Peptidase-4 Activity, DPP4 Activity Measurement 
The determination of the amount of the biological activity of dipeptidyl peptidase-4 in a sample.
National Institutes of Health

Related topics

Related topics

3 relations
CDISC SDTM Laboratory Test Terminology by CodeCDISC SDTM Laboratory Test Terminology by NameClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Circulating dipeptidyl peptidase‐4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non‐alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort…
Intrahepatic expression of dipeptidyl peptidase‐4 (DPP4), and circulating DPP4 (cDPP4) levels and its enzymatic activity, are… 
Highly Cited
2014
Highly Cited
2014
Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
Highly Cited
2013
Highly Cited
2013
GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production
The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but… 
Highly Cited
2013
Highly Cited
2013
Long‐term treatment with Sitagliptin, a dipeptidyl peptidase‐4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2‐dimethylhydrazine‐induced rats
Type 2 diabetes mellitus (T2DM) and insulin resistance (IR) increase colon cancer risk. Antidiabetic drugs stabilizing incretin… 
Highly Cited
2012
Highly Cited
2012
The increased dipeptidyl peptidase‐4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin‐treated patients
Aim: Dipeptidyl peptidase (DPP)‐4 in responsible for incretin degradation and some observations suggest that DPP‐4 activity is… 
2012
2012
Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus
Diabet. Med. 29, e205–e210 (2012) 
Highly Cited
2011
Highly Cited
2011
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
Aims/hypothesisMetformin is widely used for the treatment of type 2 diabetes. Although it reduces hepatic glucose production… 
2011
2011
Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase‐4 activity in obese patients with type 2 diabetes
The mechanism by which incretins and their effect on insulin secretion increase markedly following gastric bypass (GBP) surgery… 
Highly Cited
2009
Highly Cited
2009
Chronic Administration of Voglibose, an α-Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob…
Administration of an α-glucosidase inhibitor, voglibose, increases the secretion of glucagon-like peptide (GLP)-1, a key… 
Highly Cited
2007
Highly Cited
2007
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT
This randomized, open‐label, placebo‐controlled, 7‐period crossover study assessed dose‐response relationships following single… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)